Matching of XEN®45 and PRESERFLO™ MicroShunt cases: Outcomes of a 3-year follow-up

Both XEN and PRESERFLO effectively reduce IOP and the need for glaucoma medication, with comparable surgical success rates after 3 years. PRESERFLO demonstrated a lower revision rate and reduced frequency of early postoperative hypotony. These findings support both implants as viable options for minimally invasive glaucoma surgery, with low risk profiles.